Treatment of high-risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and culture-expanded marrow mesenchymal stem cells from a related donor with one fully mismatched human leucocyte antigen haplotype.
A 20-year-old woman with high-risk acute myelogenous leukaemia was transplanted with granulocyte colony stimulating factor (G-CSF)-mobilized peripheral blood CD34+ haematopoietic stem cells and bone-marrow-derived mesenchymal stem cells (MSC) from her human leucocyte antigen haplotype-mismatched father after myeloablative conditioning therapy. The patient engrafted rapidly and had no acute or chronic graft-versus-host disease. Since transplantation, the patient has shown an enduring trilineage haematological complete response without any evidence of leukaemia relapse at 31 months. We suggest that MSC can be used effectively for genetically haploidentical haematopoietic stem cell transplantation for acute leukaemia.
Department of Internal Medicine and BK21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea.
Seung Tae
ST
Lee
Joon Ho
JH
Jang
June-Won
JW
Cheong
Jin Seok
JS
Kim
Ho-Young
HY
Maemg
Jee Sook
JS
Hahn
Yun Woong
YW
Ko
Yoo Hong
YH
Min
D000328:Adult; D016026:Bone Marrow Transplantation; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology; D019650:Hematopoietic Stem Cell Mobilization; D006650:Histocompatibility Testing; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008212:Lymphocyte Depletion; D008297:Male; D008648:Mesoderm / Q000166:cytology; D011994:Recombinant Proteins; D033581:Stem Cell Transplantation; D013601:T-Lymphocytes; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor